Pathogenetic variants in RAD51C and RAD51D are associated with a lifetime breast cancer risk of 20 – 40%.112 Current management strategies for individuals carrying these mutations include annual mammography (MAM) and contrast-enhanced magnetic resonance imaging (MRI) screening starting at age 40. Here, RAD51D is linked to breast carcinoma.